Mara Goldstein
Stock Analyst at Mizuho
(2.54)
# 2,320
Out of 5,182 analysts
70
Total ratings
48.08%
Success rate
14.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $30 → $25 | $8.83 | +183.13% | 4 | Mar 24, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $3.38 | +195.86% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $5.46 | +46.52% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $24.80 | +69.35% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $12.15 | +311.52% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $21.11 | +113.17% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $97.74 | -21.22% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $9.90 | -29.29% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.30 | +515.38% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $83.81 | +7.39% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $15.62 | -77.59% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.53 | +23,429.41% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $5.23 | +282.41% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $110.03 | +18.15% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $4.12 | -51.46% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.48 | +710.81% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $60.69 | -67.05% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $7.93 | +505.30% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.23 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.97 | +134.51% | 1 | Oct 12, 2017 |
Kura Oncology
Mar 24, 2026
Maintains: Outperform
Price Target: $30 → $25
Current: $8.83
Upside: +183.13%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $3.38
Upside: +195.86%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.46
Upside: +46.52%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $24.80
Upside: +69.35%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $12.15
Upside: +311.52%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $21.11
Upside: +113.17%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $97.74
Upside: -21.22%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $9.90
Upside: -29.29%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.30
Upside: +515.38%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $83.81
Upside: +7.39%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $15.62
Upside: -77.59%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.53
Upside: +23,429.41%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $5.23
Upside: +282.41%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $110.03
Upside: +18.15%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $4.12
Upside: -51.46%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.48
Upside: +710.81%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $60.69
Upside: -67.05%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $7.93
Upside: +505.30%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $33.23
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.97
Upside: +134.51%